Lamivudine Generics [uk] (Lamivudine)

Lamivudine is a nucleoside reverse transcriptase inhibitor. After oral absorption it is phosphorylated inside cells to its active triphosphate form, which competes with natural nucleotides for incorporation into viral DNA. This results in premature chain termination, blocking the activity of HIV reverse transcriptase and hepatitis B polymerase.

The specific dose of lamivudine is determined by the prescribing healthcare professional based on the patient’s condition, weight, renal function and other clinical factors. Patients should follow the exact dosing instructions provided by their prescriber and not adjust the dose on their own.

The safety of lamivudine in pregnancy and lactation is not fully established. It is classified as pregnancy category unknown, so clinicians must weigh potential benefits against possible risks and discuss these considerations with the patient. Breastfeeding decisions should also be made in consultation with a healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Lamivudine belongs to the nucleoside reverse transcriptase inhibitor (NRTI) class, offering a favorable safety profile and convenient once‑daily dosing. Compared with some older NRTIs, it has lower mitochondrial toxicity and fewer metabolic side effects, making it a common component of combination antiretroviral regimens.

Lamivudine tablets should be stored at temperatures below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and avoid storing in areas with high humidity or direct sunlight.

Lamivudine is taken orally, usually as a tablet, with or without food. The tablet should be swallowed whole with a glass of water. Patients should follow the dosing schedule prescribed by their healthcare professional and maintain consistent timing each day.

Serious adverse events, though rare, include lactic acidosis, severe hepatotoxicity, pancreatitis, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be instructed to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, severe fatigue, jaundice, or skin blistering.

Lamivudine is contraindicated in individuals with known hypersensitivity to the drug or any of its excipients. Patients with severe renal or hepatic impairment should use it only under close medical supervision, and those taking contraindicated medications such as didanosine or stavudine should avoid co‑administration.